With a new fit-for-purpose facility for viral vector manufacturing currently in the design and construction phase, Avid Bioservices’ expansion into cell and gene therapy is poised to fill an observed unmet need in the space by prioritizing a customer-centric approach and emphasizing flexibility while leveraging its legacy quality record.

Considering our history and approach to customer-centricity, Avid is perfectly positioned to add value to clients in this upcoming market: 

• In contrast with many of the newer companies in the market, Avid has a very strong quality and regulatory record.
• Avid is the appropriate size to execute a customer-centric approach. 
• Avid offers a level of flexibility that’s not common with other CDMOs.